BACKGROUND AND PURPOSE: Epoxyeicosatrienoic acids (EETs) are cytochrome P450 epoxygenase metabolites of arachidonic acid that are metabolized into dihydroxyepoxyeicosatrienoic acids (DHET) by soluble epoxide hydrolase (sEH). The current investigations were performed to examine the cardioprotective effects of UA-8 (13-(3-propylureido)tridec-8-enoic acid), a synthetic compound that possesses both EET-mimetic and sEH inhibitory properties, against ischaemia-reperfusion injury. EXPERIMENTAL APPROACH: Hearts from C57BL/6 mice were perfused in Langendorff mode and subjected to ischaemia reperfusion. Mechanistic studies involved co-perfusing hearts with either 14,15-EEZE (a putative EET receptor antagonist), wortmannin or PI-103 (class-I PI3K inhibitor). H9c2 cells were utilized to investigate the protective effects against mitochondrial injury following anoxia reoxygenation. KEY RESULTS: Perfusion of UA-8 significantly improved postischaemic left ventricular developed pressure (LVDP) and reduced infarction following ischaemia reperfusion compared with control and 11,12-EET. UA-7 (13-(2-(butylamino)-2-oxoacetamido)tridec-8(Z)-enoic acid), a compound lacking sEH inhibitory properties, also improved postischaemic LVDP, while co-perfusion with 14,15-EEZE, wortmannin or PI-103 attenuated the improved recovery. UA-8 prevented anoxia-reoxygenation induced loss of mitochondrial membrane potential and cell death in H9c2 cells, which was blocked by co-treatment of PI-103. CONCLUSIONS AND IMPLICATIONS: UA-8 provides significant cardioprotection against ischaemia reperfusion injury. The effects are attributed to EETs mimetic properties, which limits mitochondrial dysfunction via class-I PI3K signalling.
BACKGROUND AND PURPOSE:Epoxyeicosatrienoic acids (EETs) are cytochrome P450 epoxygenase metabolites of arachidonic acid that are metabolized into dihydroxyepoxyeicosatrienoic acids (DHET) by soluble epoxide hydrolase (sEH). The current investigations were performed to examine the cardioprotective effects of UA-8 (13-(3-propylureido)tridec-8-enoic acid), a synthetic compound that possesses both EET-mimetic and sEH inhibitory properties, against ischaemia-reperfusion injury. EXPERIMENTAL APPROACH: Hearts from C57BL/6 mice were perfused in Langendorff mode and subjected to ischaemia reperfusion. Mechanistic studies involved co-perfusing hearts with either 14,15-EEZE (a putative EET receptor antagonist), wortmannin or PI-103 (class-I PI3K inhibitor). H9c2 cells were utilized to investigate the protective effects against mitochondrial injury following anoxia reoxygenation. KEY RESULTS: Perfusion of UA-8 significantly improved postischaemic left ventricular developed pressure (LVDP) and reduced infarction following ischaemia reperfusion compared with control and 11,12-EET. UA-7 (13-(2-(butylamino)-2-oxoacetamido)tridec-8(Z)-enoic acid), a compound lacking sEH inhibitory properties, also improved postischaemic LVDP, while co-perfusion with 14,15-EEZE, wortmannin or PI-103 attenuated the improved recovery. UA-8 prevented anoxia-reoxygenation induced loss of mitochondrial membrane potential and cell death in H9c2 cells, which was blocked by co-treatment of PI-103. CONCLUSIONS AND IMPLICATIONS: UA-8 provides significant cardioprotection against ischaemia reperfusion injury. The effects are attributed to EETs mimetic properties, which limits mitochondrial dysfunction via class-I PI3K signalling.
Authors: Ketul R Chaudhary; Sri Nagarjun Batchu; Dipankar Das; Mavanur R Suresh; John R Falck; Joan P Graves; Darryl C Zeldin; John M Seubert Journal: Cardiovasc Res Date: 2009-04-28 Impact factor: 10.787
Authors: Yunfang Zhang; Haitham El-Sikhry; Ketul R Chaudhary; Sri Nagarjun Batchu; Anooshirvan Shayeganpour; Taibeh Orujy Jukar; J Alyce Bradbury; Joan P Graves; Laura M DeGraff; Page Myers; Douglas C Rouse; Julie Foley; Abraham Nyska; Darryl C Zeldin; John M Seubert Journal: Am J Physiol Heart Circ Physiol Date: 2009-05-08 Impact factor: 4.733
Authors: Marc Revermann; Eduardo Barbosa-Sicard; Eva Dony; Ralph T Schermuly; Christophe Morisseau; Gerd Geisslinger; Ingrid Fleming; Bruce D Hammock; Ralf P Brandes Journal: J Hypertens Date: 2009-02 Impact factor: 4.844
Authors: Yuli Xie; Yidong Liu; Gangli Gong; Deborah H Smith; Fang Yan; Alison Rinderspacher; Yan Feng; Zhengxiang Zhu; Xiangpo Li; Shi-Xian Deng; Lars Branden; Dusica Vidović; Caty Chung; Stephan Schürer; Christophe Morisseau; Bruce D Hammock; Donald W Landry Journal: Bioorg Med Chem Lett Date: 2008-09-20 Impact factor: 2.823
Authors: Suman Kundu; Talat Roome; Ashish Bhattacharjee; Kevin A Carnevale; Valentin P Yakubenko; Renliang Zhang; Sung Hee Hwang; Bruce D Hammock; Martha K Cathcart Journal: J Lipid Res Date: 2012-11-15 Impact factor: 5.922
Authors: Yingmei Liu; Xiaodan Lu; Sinh Nguyen; Jean L Olson; Heather K Webb; Deanna L Kroetz Journal: Mol Pharmacol Date: 2013-10-03 Impact factor: 4.436
Authors: Md Abdul Hye Khan; Jan Neckár; Vijay Manthati; Ramu Errabelli; Tengis S Pavlov; Alexander Staruschenko; John R Falck; John D Imig Journal: Hypertension Date: 2013-08-26 Impact factor: 10.190